Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice

Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice

Introduction and Purpose: Adalimumab, a TNF-α inhibitor, is a cornerstone treatment for autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Despite its efficacy, the high cost of adalimumab (Humira®) limits accessibility. The emergence of biosimilars o...

Full description

Saved in:
Bibliographic Details
Main Authors: Dorota Waz, Michał Mazur, Jakub Szarłowicz, Zofia Goliszek, Karolina Łucja Sobek, Wiktoria Tabin-Barczak, Aldona Sokołowska, Klaudia Fikas, Kamil Chwaliszewski, Sebastian Samuła
Format: Article
Language:English
Published: Nicolaus Copernicus University in Toruń 2025-01-01
Series:Quality in Sport
Subjects:
adalimumab
biosimilars
Inflammatory Bowel Disease
ankylosing spondylitis
TNF-alpha (TNF-α)
Rheumatoid arthritis (RA)
Online Access:https://apcz.umk.pl/QS/article/view/57232
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://apcz.umk.pl/QS/article/view/57232

Similar Items